Published in Am J Gastroenterol on August 16, 2011
Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol (2014) 1.02
A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit (2014) 0.91
Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol (2014) 0.90
Second Korean guidelines for the management of ulcerative colitis. Intest Res (2017) 0.83
Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.77
Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. Aliment Pharmacol Ther (2014) 0.75
Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn's Disease. ACG Case Rep J (2017) 0.75
Current opinion on treatment of inflammatory bowel disease in pregnant women. Arch Med Sci (2012) 0.75
Risk of lymphoma in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2012) 0.75
Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.75
IBD: Step-up vs top-down therapy for Crohn's disease: medicine vs surgery. Nat Rev Gastroenterol Hepatol (2017) 0.75
Early histological findings may predict the clinical phenotype in Crohn's colitis. United European Gastroenterol J (2016) 0.75
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med (2012) 5.80
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut (2011) 4.79
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Crohn's disease. Lancet (2012) 4.42
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology (2013) 3.55
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Ulcerative colitis. Lancet (2012) 3.38
The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol (2008) 3.30
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Mucosal healing in inflammatory bowel diseases: a systematic review. Gut (2012) 3.02
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 2.91
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut (2010) 2.82
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology (2007) 2.76
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 2.74
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc (2006) 2.73
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis (2012) 2.55
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A (2013) 2.53
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol (2008) 2.50
Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol (2004) 2.45
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Use of abdominopelvic computed tomography in emergency departments and rates of urgent diagnoses in Crohn's disease. Clin Gastroenterol Hepatol (2011) 2.40
Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol (2013) 2.39
Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am (2002) 2.37
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology (2006) 2.34
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology (2012) 2.26
Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23